You are here: HomeBusiness › Astellas to buy U.S. genetic medicine developer Audentes for $3 billion

Business

Astellas to buy U.S. genetic medicine developer Audentes for $3 billion

via The Japan Times    Dec 03, 2019
Credit : JIJI

Astellas Pharma Inc. said Tuesday that it will buy U.S. genetic medicine developer Audentes Therapeutics Inc. for some $3 billion.

The Japanese company hopes to complete the acquisition of the San Francisco-based company through a tender offer by the end of March next year.